A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA in Subjects With Mild to Moderate Huntington's Disease

Trial Profile

A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA in Subjects With Mild to Moderate Huntington's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2009

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Acronyms TREND-HD
  • Most Recent Events

    • 09 Apr 2009 Marketing Authorization Application has been accepted for review by the European Medicines Agency, according to a Amarin Corporation media release.
    • 10 Aug 2006 The expected completion date for this trial is now 1 Sep 2007.
    • 01 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top